Track 3: Benefit-Risk Assessment

Benefit-Risk Assessment examines systematic methods for comparing the therapeutic benefits of medicines with their potential risks. Topics include clinical evidence evaluation, safety outcomes, treatment effectiveness, uncertainty, patient perspectives, and evolving benefit-risk frameworks. The track explores how benefit-risk information can be assessed throughout drug development and after approval. Researchers can discuss innovative methodologies for supporting transparent and evidence-based therapeutic decisions.

 

    Related Conference of Track 3: Benefit-Risk Assessment

    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2026

    5th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 26-27, 2026

    5th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    December 14-15, 2026

    5th Global Summit on Pharmaceutical Research

    Paris, France
    January 26-27, 2027

    22nd Annual Meet on Pharmaceutical Sciences

    Paris, France
    February 15-16, 2027

    23rd Annual Congress on Pharmacology and Toxicology

    Paris, France
    February 22-23, 2027

    41st World Congress on Pharmacology and Therapeutics

    Amsterdam, Netherlands
    April 08-09, 2027

    21st World Drug Delivery Summit

    Vienna, Austria
    April 27-28, 2027

    10th European Biopharma Congress

    Paris, France
    April 27-28, 2027

    19th World Drug Delivery Summit

    Paris, France

    Track 3: Benefit-Risk Assessment Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in